What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Psychiatry
- Major depressive disorder
His primary areas of study are Psychiatry, Antipsychotic, Bipolar disorder, Young adult and Pediatrics.
His Schizophrenia study in the realm of Psychiatry interacts with subjects such as Accidental.
His research links Mood with Antipsychotic.
His Bipolar disorder research focuses on Quetiapine and how it connects with Randomized controlled trial.
The Young adult study combines topics in areas such as Retrospective cohort study and Obstetrics.
His Pediatrics research includes elements of Nausea, Antidepressant medication and Discontinuation.
His most cited work include:
- Antipsychotics and the Risk of Type 2 Diabetes Mellitus in Children and Youth (145 citations)
- Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. (142 citations)
- Prevalence of Multimorbidity in a Geographically Defined American Population: Patterns by Age, Sex, and Race/Ethnicity (121 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Psychiatry, Bipolar disorder, Internal medicine, Depression and Major depressive disorder.
His Psychiatry study incorporates themes from Tolerability and Pediatrics.
His Bipolar disorder research is multidisciplinary, relying on both Quetiapine and Clinical psychology, Mood.
His biological study spans a wide range of topics, including Schizoaffective disorder, Endocrinology, Olanzapine and Atypical antipsychotic.
The Depression study combines topics in areas such as Medical prescription and Comorbidity.
His Major depressive disorder research also works with subjects such as
- Escitalopram that intertwine with fields like Citalopram and Serotonin reuptake inhibitor,
- Antidepressant together with Fluoxetine.
He most often published in these fields:
- Psychiatry (50.00%)
- Bipolar disorder (29.01%)
- Internal medicine (29.01%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (29.01%)
- Major depressive disorder (16.67%)
- Depression (23.46%)
In recent papers he was focusing on the following fields of study:
His main research concerns Internal medicine, Major depressive disorder, Depression, Citalopram and Bipolar disorder.
The study incorporates disciplines such as Treatment-resistant depression and Oncology in addition to Internal medicine.
He is investigating Endocrinology and Psychiatry as part of his examination of Depression.
William V. Bobo works on Psychiatry which deals in particular with Depressive symptoms.
His work deals with themes such as Venlafaxine and Escitalopram, which intersect with Citalopram.
His Bipolar disorder research is multidisciplinary, incorporating perspectives in Generalized anxiety disorder and Clinical psychology, Mood.
Between 2018 and 2021, his most popular works were:
- Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations (38 citations)
- Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication (25 citations)
- Association of Cytomegalovirus and Toxoplasma gondii Antibody Titers With Bipolar Disorder. (9 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Major depressive disorder
- Psychiatry
William V. Bobo mostly deals with Internal medicine, Body mass index, Bipolar disorder, Depression and Citalopram.
His study in Body mass index is interdisciplinary in nature, drawing from both Binge eating, Treatment-resistant depression and Intravenous ketamine.
He has included themes like Polypharmacy, Generalized anxiety disorder, Unmeasured confounding and Medication adherence in his Bipolar disorder study.
His Depression research entails a greater understanding of Psychiatry.
His Citalopram study integrates concerns from other disciplines, such as Confounding, Escitalopram and Serotonin reuptake inhibitor.
His Escitalopram research is multidisciplinary, incorporating elements of Major depressive disorder and Pharmacogenomics.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
